The Priority Review

Tag

Boehringer Ingelheim

1 story

  1. Clinical trials

    Boehringer Ingelheim registers study of survodutide in overweight or obesity without diabetes

    This study was first posted on ClinicalTrials.gov on October 2, 2026. The Phase IIIb, open-label study plans to enroll 350 participants, with a planned start date of November 7, 2026 and a primary completion date of June 25, 2028.